Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells

Journal of Cellular Physiology

Volumn 184, Issue 2, 2000, Pages 246-254

  Montaldo, Fabrizio ^a   Maffé, Antonella ^b   Morini, Monica ^c   Noonan, Douglas ^c   Giordano, Silvia ^b   Albini, Adriana ^d   Prat, Maria ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c CENTRO DI BIOTECNOLOGIE AVANZATE   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL IMMORTALIZATION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; KAPOSI SARCOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

ANIMALS; CELL COUNT; ENDOTHELIAL GROWTH FACTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; LYMPHOKINES; MICE; PROTEIN ISOFORMS; PROTEIN-TYROSINE KINASES; SARCOMA, KAPOSI; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

MUS MUSCULUS;

EID: 0033949086     PISSN: 00219541     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-4652(200008)184:2<246::AID-JCP13>3.0.CO;2-O     Document Type: Article

References (52)

1. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. 1987. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
2. Albini A, Soldi R, Giunciuglio D, Giraudo E, Benelli R, Primo L, Noonan D, Salio M, Camussi G, Rockl W, Bussolino F. 1996. The angiogenesis induced by HIV-1 tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 2:1371-1375.
3. Albini A, Paglieri I, Orengo G, Carlone S, Aluigi MG, DeMarchi R, Matteucci C, Mantovani A, Carozzi F, Donini S, Benelli R. 1997. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS 11:713-721.
4. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM, Schettini G. 1999. Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. Faseb J 13:647-655.
5. Ascherl G, Hohenadl C, Schatz O, Shumay E, Bogner J, Eckhart L, Tschachler E, Monini P, Ensoli B, Sturzl M. 1999. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood 93:4232-4241.
6. Barillari G, Sgadari C, Palladino C, Gendelman R, Caputo A, Morris CB, Nair BC, Markham P, Nel A, Sturzl M, Ensoli B. 1999. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 163:1929-1935.
7. Birchmeier C, Gherardi E. 1998. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol 8:4404-4410.
8. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. 1992. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 119:629-641.
9. Bussolino F, Mantovani A, Persico G. 1997. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22:251-256.
10. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380:435-439.
11. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. 1984. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311: 29-33.
12. Cornali E, Zietz C, Benelli R, Weninger W, Masiello L, Breier G, Tschachler E, Albini A, Sturzl M. 1996. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol 149:1851-1869.
13. Cottoni F. 1996. Reticuloendothelial origin and metastasis of Kaposi's sarcoma: historical update on the literature. Blood 87:2605.
14. Ensoli B, Sturzl M. 1998. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines angiogenic factors and viral agents. Cytokine Growth Factor Rev 9:63-83.
15. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. 1996. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442.
16. Ferrara N. 1999. Molecular and biological properties of vascular endothelial growth factor. J Mol. Med 77:527-543.
17. Folkman J. 1995. Angiogenesis in cancer vascular rheumatoid and other disease. Nat Med 1:27-31.
18. Ganju RK, Munshi N, Nair BC, Liu ZY, Gill P, Groopman JE. 1998. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 72:6131-6137.
19. Gaudino G, Follenzi A, Naldini L, Collesi C, Santoro M, Gallo KA, Godowski J, Comoglio PM. 1994. Ron is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J 13:3524-3532.
20. Gaudino G, Avantaggiato V, Follenzi A, Acampora D, Simeone A, Comoglio PM. 1995. The proto-oncogene RON is involved in development of epithelial, bone and neuro-endocrine tissues. Oncogene 11:2627-2637.
21. Giordano S, Ponzetto C, Di Renzo MF, Cooper CS, Comoglio PM. 1989. Tyrosine kinase receptor indistinguishable from the c-met protein. Nature 339:155-156.
22. Graziani A, Gramaglia D, Cantley LC, Comoglio PM. 1991. The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. J Biol Chem 266:22087-22090.
23. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. 1991. The vascular endothelial growth factor family: identification of afourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814.
24. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. 1997. Activating mutations for the Met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 94:11445-11450.
25. Kobayashi H, Ohi H, Sugimura M, Shinohara H, Fujii T, Terao T. 1992. Inhibition of in vitro ovarian cancer cell invasion by modulation of urokinase-type plasminogen activator and cathepsin B. Cancer Res 52:3610-3614.
26. Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 230:680-685.
27. Lunardi-Iskandar Y, Gill P, Lam VH, Zeman RA, Michaels F, Mann DL, Reitz MS Jr, Kaplan M, Berneman ZN, Carter D, et al. 1995. Isolation and characterization of an immortal neoplastic cell line (KS Y-1) from AIDS-associated Kaposi's sarcoma. J Natl Cancer Inst 87:974-981.
28. Maier JA, Mariotti M, Albini A, Comi P, Prat M, Comoglio PM, Soria MR. 1996. Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. Int J Cancer 65:168-172.
29. Marchiò S, Primo L, Pagano M, Palestro G, Albini A, Veikkola T, Cascone I, Alitalo K, Bussolino F. 1999. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem Sep 274:27617-27622.
30. Marconcini L, Marchiò S, Morbidelli L, Cartocci E, Albini A, Ziche M, Bussolino F, Oliviero S. 1999. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci USA 96:9671-9676.
31. Masood R, Cai J, Zheng T, Smith DL, Naidu Y, Gill PS. 1997. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 94:979-984.
32. Medico E, Mongiovi AM, Huff J, Jelinek MA, Follenzi A, Gaudino G, Parsons JT, Comoglio PM. 1996. The tyrosine kinase receptors Ron and Sea control "scattering" and morphogenesis of liver progenitor cells in vitro. Mol Biol Cell 7:1-10.
33. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. 1992. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11:4825-4833.
34. Naldini L, Vigna E, Bardelli A, Follenzi A, Galimi F, Comoglio PM. 1995. Biological activation of pro-HGF (Hepatocyte growth factor) by urokinase is controlled in vivo by a stoichiometric reaction. J Biol Chem 270:603-611.
35. Naidu YM, Rosen EM, Zitnick R, Goldberg I, Park M, Naujokas M, Polverini PJ, Nickoloff BJ. 1994. Role of scatter factor in the pathogenesis of AIDS-related Kaposi sarcoma. Proc Natl Acad Sci USA 91:5281-5285.
36. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22.
37. Ponzetto C, Giordano S, Peverali F, Della Valle G, Abate ML, Vaula G, Comoglio PM. 1991. c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase. Oncogene 6:553-559.
38. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P, Giordano S, Graziani A, Panayotou G, Comoglio PM. 1994. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77:261-271.
39. Porter AC, Vaillancourt RR. 1998. Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17:1343-1352.
40. Prat M, Crepaldi T, Gandino L, Giordano S, Longati P, Comoglio P. 1991a. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 11:5954-5962.
41. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. 1998. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci 111:237-247.
42. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. 1991b. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes epithelial cells and solid tumors. Int J Cancer 49:323-328.
43. Reitz MS Jr, Nerurkar LS, Gallo RC. 1999. Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. J Natl Cancer Inst 91: 1453-1458.
44. Ruco LP, Ranalli T, Marzullo A, Bianco P, Prat M, Comoglio PM, Baroni CD. 1996. Expression of Met protein in thyroid tumors. J Pathol 180:266-270.
45. Siegal B, Levinton-Kriss S, Schiffer A, Sayar J, Engelberg I, Vonsover A, Ramon Y, Rubinstein E. 1990. Kaposi's sarcoma in immunosuppression. Possibly the result of a dual viral infection. Cancer 65:492-498.
46. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X, Robinson G, Driver S, Bischoff J, Zhang B, Schaeffer JM, Senger DR. 1999. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 5:1390-1395.
47. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. 1993. Scatter factor/hepatocyte growth factor and its receptor the c-met tyrosine kinase can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123:223-235.
48. Tamagnone L, Comoglio PM. 1997. Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors. Cytokine Growth Factor Rev 8:129-142.
49. Trusolino L, Pugliese L, Comoglio PM. 1998. Interactions between scatter factors and their receptors: hints for therapeutic applications. FASEB J 12:1267-1280.
50. Van der Geer P, Hunter T, Lindberg RA. 1994. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 10:251-337.
51. Weidner KM, Behrens J, Vandekerckhove J, Birchmeier W. 1990. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J Cell Biol 111:2097-2108.
52. Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L. 1999. Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody. Cancer Lett 136:203-213.